Status:
COMPLETED
Unlocking Dystonia From Parkinson's Disease With Directional DBS Technology
Lead Sponsor:
University of Alabama at Birmingham
Collaborating Sponsors:
Michael J. Fox Foundation for Parkinson's Research
Conditions:
Dystonia-Parkinsonism, Adult-Onset
Parkinson Disease
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
This study occurs during five visits that are already scheduled as part of "Biomarkers to Guide Directional DBS for Parkinson's Disease" (ClinicalTrials.gov Identifier: NCT03353688). If participants h...
Detailed Description
To measure the effects of DBS on dystonia, the investigators will measure the change in the Burke-Fahn-Marsden Dystonia Rating Scale at 2, 4, 6, and 12 months after surgery versus preoperative baselin...
Eligibility Criteria
Inclusion
- Enrollment in "Biomarkers to Guide Directional DBS for Parkinson's Disease" (ClinicalTrials.gov Identifier: NCT03353688)
- Diagnosis of Parkinson's disease with and without dystonia
Exclusion
- Not enrolled in "Biomarkers to Guide Directional DBS for Parkinson's Disease" (ClinicalTrials.gov Identifier: NCT03353688)
Key Trial Info
Start Date :
January 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2022
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT03409120
Start Date
January 1 2018
End Date
June 30 2022
Last Update
November 10 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294